SG10202100598RA - Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity - Google Patents

Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Info

Publication number
SG10202100598RA
SG10202100598RA SG10202100598RA SG10202100598RA SG10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA SG 10202100598R A SG10202100598R A SG 10202100598RA
Authority
SG
Singapore
Prior art keywords
fusion protein
binding capacity
extracellular vesicle
vesicle
extracellular
Prior art date
Application number
SG10202100598RA
Inventor
André Görgens
Dhanu Gupta
Oscar WIKLANDER
Original Assignee
Evox Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Evox Therapeutics Ltd filed Critical Evox Therapeutics Ltd
Publication of SG10202100598RA publication Critical patent/SG10202100598RA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/44—Antibodies bound to carriers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/46—Ingredients of undetermined constitution or reaction products thereof, e.g. skin, bone, milk, cotton fibre, eggshell, oxgall or plant extracts
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6901—Conjugates being cells, cell fragments, viruses, ghosts, red blood cells or viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A61K47/6913—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome the liposome being modified on its surface by an antibody
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/305—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F)
    • C07K14/31—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Micrococcaceae (F) from Staphylococcus (G)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/32—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against translation products of oncogenes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G01N33/554—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals the carrier being a biological cell or cell fragment, e.g. bacteria, yeast cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/705—Fusion polypeptide containing domain for protein-protein interaction containing a protein-A fusion

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Hematology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
SG10202100598RA 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity SG10202100598RA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GB1612643.5A GB2552473A (en) 2016-07-21 2016-07-21 Surface decoration of extracellular vesicles

Publications (1)

Publication Number Publication Date
SG10202100598RA true SG10202100598RA (en) 2021-02-25

Family

ID=56894359

Family Applications (4)

Application Number Title Priority Date Filing Date
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
SG11201811152YA SG11201811152YA (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811151PA SG11201811151PA (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity
SG10202100598RA SG10202100598RA (en) 2016-07-21 2017-07-21 Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity

Family Applications Before (3)

Application Number Title Priority Date Filing Date
SG10202100597TA SG10202100597TA (en) 2016-07-21 2017-07-21 Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
SG11201811152YA SG11201811152YA (en) 2016-07-21 2017-07-21 Uses of extracellular vesicle comprising a fusion protein having fc binding capacity
SG11201811151PA SG11201811151PA (en) 2016-07-21 2017-07-21 Extracellular vesicle comprising a fusion protein having fc binding capacity

Country Status (12)

Country Link
US (3) US11236143B2 (en)
EP (3) EP3487529A1 (en)
JP (4) JP7254016B2 (en)
KR (2) KR102636776B1 (en)
CN (2) CN109689097B (en)
AU (2) AU2017300035A1 (en)
BR (2) BR112019001099A2 (en)
CA (2) CA3031186A1 (en)
GB (1) GB2552473A (en)
MX (2) MX2019000863A (en)
SG (4) SG10202100597TA (en)
WO (2) WO2018015539A1 (en)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20130280334A1 (en) 2010-09-24 2013-10-24 Massachusetts Institute Of Technology Nanostructured Gels Capable of Controlled Release of Encapsulated Agents
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles
WO2018144991A1 (en) 2017-02-03 2018-08-09 The Brigham And Women's Hospital, Inc. Self-assembled gels formed with anti-retroviral drugs, prodrugs thereof, and pharmaceutical uses thereof
GB2597623A (en) 2017-08-07 2022-02-02 Univ California Platform for generating safe cell therapeutics
GB201717446D0 (en) * 2017-10-24 2017-12-06 Evox Therapeutics Ltd Affinity purification of engineering extracellular vesicles
GB201804291D0 (en) * 2018-03-16 2018-05-02 Evox Therapeutics Ltd Cell-mediated exosome delivery
AU2019247375B2 (en) 2018-04-04 2022-08-04 Alivio Therapeutics, Inc. Self-assembled gels for controlled delivery of biologics and methods of making thereof
US11266603B2 (en) * 2018-06-28 2022-03-08 Academia Sinica Synthetic polypeptides and uses thereof
EP3823983A4 (en) * 2018-07-20 2022-05-18 The Board of Trustees of the Leland Stanford Junior University Soluble polypeptides and methods of using same for inhibiting leukemia inhibitory factor activity
JP2021533834A (en) 2018-08-14 2021-12-09 エバーサイト・ゲーエムベーハー Target-specific extracellular vesicles
CN108998402B (en) * 2018-08-28 2020-05-29 江南大学 Recombinant bacillus subtilis and construction method and application thereof
US20210317479A1 (en) 2018-09-06 2021-10-14 The Broad Institute, Inc. Nucleic acid assemblies for use in targeted delivery
JP2022505159A (en) * 2018-10-19 2022-01-14 オハイオ・ステイト・イノベーション・ファウンデーション Extracellular vesicles for targeted therapy against myeloid-derived suppressor cells
CN113271928A (en) * 2018-10-19 2021-08-17 俄亥俄州国家创新基金会 Nanocarriers for pulmonary inflammation treatment
AU2019378108A1 (en) * 2018-11-16 2021-05-27 Evox Therapeutics Ltd Extracellular vesicles for replacement of urea cycle proteins and nucleic acids
CA3125067A1 (en) * 2018-12-27 2020-07-02 Akeso Biopharma, Inc. Antibody against human il-4ra and use thereof
WO2020163370A1 (en) * 2019-02-04 2020-08-13 Codiak Biosciences, Inc. Membrane protein scaffolds for exosome engineering
WO2020227369A1 (en) * 2019-05-06 2020-11-12 Malcolm Thomas Tailored hypoimmune nanovesicular delivery systems for cancer tumors
CN114258398A (en) * 2019-06-13 2022-03-29 总医院公司 Engineered human endogenous virus-like particles and methods of delivery to cells using the same
WO2020249757A1 (en) * 2019-06-14 2020-12-17 Philogen S.P.A Immunoconjugates comprising a single chain diabody and interleukin-15 or interleukin-15 and a sushi domain of interleukin-15 receptor alpha
CN114269360A (en) * 2019-06-21 2022-04-01 恩特莱科索生物治疗公司 Platforms, compositions and methods for therapeutic delivery
EP4009989A4 (en) * 2019-08-06 2023-08-23 Ohio State Innovation Foundation Therapeutic extracellular vesicles
WO2021045501A1 (en) * 2019-09-02 2021-03-11 경북대학교 산학협력단 Composition for preventing or treating cancer, containing il-2 surface expression-extracellular vesicles as active ingredient
CN112941028A (en) * 2019-12-09 2021-06-11 上海细胞治疗集团有限公司 Nano antibody gene modified mesenchymal stem cell and preparation method and application thereof
KR20220139926A (en) 2020-02-05 2022-10-17 다이아뎀 바이오쎄라퓨틱스 인크 artificial synapse
WO2021211460A1 (en) * 2020-04-13 2021-10-21 City Of Hope Cell-receptor targeted exosomes
CN111544453B (en) * 2020-04-27 2021-01-22 高连如 Mixed stem cell injection containing three angiogenesis attributes and preparation method thereof
CN111560352B (en) * 2020-06-02 2023-03-24 新疆农业大学 Virus-like vesicle and preparation method and application thereof
CN111905105B (en) * 2020-07-02 2023-05-05 华南师范大学 Protein nano-drug for cancer targeted therapy and preparation method thereof
CN112111513A (en) * 2020-07-17 2020-12-22 深圳市第二人民医院 Preparation method of novel coronavirus vaccine based on exosome platform
CN113967254B (en) * 2020-08-04 2022-08-12 华南理工大学 Cell membrane coated nano aptamer for multi-specific antibody delivery and application
CN116782932A (en) * 2020-08-05 2023-09-19 俄亥俄州国家创新基金会 Adapter polypeptides and methods of use thereof
CN112285195B (en) * 2020-10-27 2021-08-10 江南大学 Characteristic glycoprotein marker of milk exosome and characteristic marker separation method of milk exosome
WO2022149779A1 (en) * 2021-01-11 2022-07-14 주식회사 엑소코바이오 Exosome comprising overexpressed fc receptor or portion thereof, and method for preparing same
KR102252325B1 (en) * 2021-01-14 2021-05-14 이장호 Production Methods of Immune-tolerant Extracellular Vesicles containing fetal-derived primal immunoglobulins
WO2022158836A1 (en) * 2021-01-21 2022-07-28 주식회사 엑소코바이오 Recombinant exosome comprising fc receptor or portion thereof to which target protein or peptide is fusible, and use thereof
AU2022259546A1 (en) * 2021-04-14 2023-11-16 Anjarium Biosciences Ag Fc-derived polypeptides
AU2022258759A1 (en) * 2021-04-14 2023-11-23 Anjarium Biosciences Ag Peptides, nanovesicles, and uses thereof for drug delivery
GB202107182D0 (en) * 2021-05-19 2021-06-30 Evox Therapeutics Ltd Nanoparticle delivery system for production of engineered extracellular vesicles
CN113599516B (en) * 2021-08-16 2022-02-18 上海蒙彼利生物技术有限公司 Method for preparing exosome and application of pharmaceutical composition thereof in tissue repair
KR20230039788A (en) * 2021-09-08 2023-03-21 주식회사 꿈랩 Plasmid platform for stable delivery of nucleic acid molecules
CN113897387B (en) * 2021-10-09 2023-09-05 深圳市汉科生命工程有限公司 Preparation method and application of gene recombinant MSC (moving bed memory) with hair regeneration promoting function and exosome-like nanomaterial thereof
CN114236113B (en) * 2021-12-21 2023-07-21 南京农业大学 2, 4-drop instant immunosensor
WO2023133425A1 (en) * 2022-01-04 2023-07-13 The Broad Institute, Inc. Compositions and methods for delivering cargo to a target cell
WO2023196586A1 (en) * 2022-04-07 2023-10-12 The Regents Of The University Of Michigan Methods and devices for screening extracellular vesicles
CN117802045A (en) * 2022-09-30 2024-04-02 北京恩康医药有限公司 Construction and application of engineering extracellular vesicles

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999059643A2 (en) * 1998-05-20 1999-11-25 Sdg, Inc. Liposomal delivery complex
US20040241176A1 (en) * 2000-04-27 2004-12-02 Ap Cells. Inc. Method of producing membrane vesicles
US20070128117A1 (en) * 2003-02-04 2007-06-07 Bracco International B.V. Ultrasound contrast agents and process for the preparation thereof
JP2007295929A (en) 2006-04-05 2007-11-15 Geno Membrane:Kk Canine bsep gene
US8637477B2 (en) * 2007-08-30 2014-01-28 Akshaya Bio Inc. Antigenic compositions and use of same in the targeted delivery of nucleic acids
US8282930B2 (en) * 2007-09-24 2012-10-09 The University Of Queensland Molecular delivery vehicle
ES2927225T3 (en) 2009-04-17 2022-11-03 Univ Oxford Innovation Ltd Composition for delivery of genetic material
JP6012624B2 (en) * 2010-12-23 2016-10-25 ヤンセン バイオテツク，インコーポレーテツド Active protease resistant antibody Fc mutant
JP6199746B2 (en) * 2011-02-15 2017-09-20 バキシオン セラピューティクス，リミテッド ライアビリティ カンパニー Bacterial minicell therapeutic compositions and methods for targeted delivery of bioactive molecules based on antibodies and Fc-containing targeting molecules
GB201121069D0 (en) 2011-12-07 2012-01-18 Isis Innovation Delivery system
GB201121070D0 (en) 2011-12-07 2012-01-18 Isis Innovation composition for delivery of biotherapeutics
AU2014251388B2 (en) * 2013-04-12 2017-03-30 Evox Therapeutics Limited Therapeutic delivery vesicles
WO2015002956A1 (en) 2013-07-01 2015-01-08 Ohio State Innovation Foundation Exosome delivery system
US10538570B2 (en) * 2013-09-30 2020-01-21 Northwestern University Targeted and modular exosome loading system
US20160243192A1 (en) 2013-10-17 2016-08-25 Children's Hospital Los Angeles Antibody dependent exosome therapy
WO2015143113A1 (en) * 2014-03-20 2015-09-24 Barb Ariel Cohen Preparations of derived extracellular vesicles, assays, and methods to modify therapeutic outcomes using such preparations
GB2552473A (en) * 2016-07-21 2018-01-31 Evox Therapeutics Ltd Surface decoration of extracellular vesicles

Also Published As

Publication number Publication date
KR102636776B1 (en) 2024-02-15
CA3031183A1 (en) 2018-01-25
EP3487528A1 (en) 2019-05-29
GB2552473A (en) 2018-01-31
US20200109183A1 (en) 2020-04-09
US20220098267A1 (en) 2022-03-31
EP3487529A1 (en) 2019-05-29
AU2017299214A1 (en) 2019-02-07
GB201612643D0 (en) 2016-09-07
AU2017300035A1 (en) 2019-02-07
CN109689097B (en) 2023-01-03
JP2019524745A (en) 2019-09-05
CN109689097A (en) 2019-04-26
CN109689098A (en) 2019-04-26
SG11201811152YA (en) 2019-01-30
MX2019000861A (en) 2019-09-04
MX2019000863A (en) 2019-09-04
KR20190032479A (en) 2019-03-27
KR20190032480A (en) 2019-03-27
EP4299137A3 (en) 2024-04-10
US11236143B2 (en) 2022-02-01
SG10202100597TA (en) 2021-02-25
EP3487528B1 (en) 2023-08-30
JP7254016B2 (en) 2023-04-07
JP2023026440A (en) 2023-02-24
EP4299137A2 (en) 2024-01-03
CA3031186A1 (en) 2018-01-25
US20230181757A1 (en) 2023-06-15
JP2022117998A (en) 2022-08-12
WO2018015535A1 (en) 2018-01-25
BR112019001099A2 (en) 2019-06-25
SG11201811151PA (en) 2019-01-30
WO2018015539A1 (en) 2018-01-25
BR112019001108A2 (en) 2019-07-02
JP7140743B2 (en) 2022-09-21
JP2019523407A (en) 2019-08-22

Similar Documents

Publication Publication Date Title
SG10202100598RA (en) Uses of Extracellular Vesicle Comprising a Fusion Protein Having FC Binding Capacity
IL275426A (en) Engineered il-2 fc fusion proteins
HK1244019A1 (en) Fusion proteins
ZA201701810B (en) Sirp-alpha immunoglobulin fusion proteins
EP3233920A4 (en) Single chain fc fusion proteins
EP3502143A4 (en) Linker peptide for constructing fusion protein
IL274124A (en) Protein engineered extracellular vesicles
HK1258125A1 (en) Insulin immunoglobulin fusion proteins
HRP20182029T1 (en) Uti fusion proteins
EP2969009A4 (en) Modified fc fusion proteins
ZA202003845B (en) Fusion proteins
EP3099320A4 (en) Protein m related immunoglobulin-binding polypeptides
EP3464384A4 (en) Fusion protein construct
GB201602850D0 (en) Fusion proteins
EP3649159C0 (en) Fusion protein
GB201712792D0 (en) Fusion protein
EP3368552A4 (en) A fusion protein crystal comprising a moiety